Status and phase
Conditions
Treatments
About
To determine the pharmacokinetics and safety of megestrol acetate after a single oral 300 mg dose of megestrol acetate concentrated suspension in healthy subjects, and subjects with varying degrees of renal impairment
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Healthy Subjects with Normal Renal Function
Subjects with Mild, Moderate, or Severe Renal Impairment or ESRD
Meet inclusion criteria 1 through 3 for healthy subjects and the following criteria:
Exclusion criteria
Healthy Subjects with Normal Renal Function
Subjects with Mild, Moderate, or Severe Renal Impairment or ESRD
Excluded if subjects meet exclusion criteria 4 through 13 for healthy subjects and the following criteria:
7 participants in 5 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal